In a recent study, a patient with metastatic and refractory choriocarcinoma following a combination of chemotherapy and surgical metastectomy achieved complete remission after receiving therapy with an anti-CD105 monoclonal antibody (TRC105) and bevacizumab, which indicated that CD105 is a potential novel drug target for overcoming chemoresistance in choriocarcinoma 6. Here, ENG is linked to choriocarcinoma.